Virdante Pharmaceuticals, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2008 | $30 M | No. 1 | $10 to $50 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Virdante Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2011).
SEC Form D · Oct 2011
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Oct 2011
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Virdante Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| John Ripple | Executive officer | Oct 2011 |
| Anders Patrick Hove | Director | Oct 2011 |
| Eric Patrick Aguiar | Director | Oct 2011 |
| Gail Patrick Wasserman | Director | Oct 2011 |
| John Ripple | Director | Oct 2011 |
| L. Patrick Gage | Director | Oct 2011 |
| Michael Patrick Steinmetz | Director | Oct 2011 |